Nektar Therapeutics

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi & O’Reilly, LLP is investigating possible securities fraud claims against Nektar (Nasdaq: NKTR) resulting from inaccurate statements Whiting made regarding its business practices, financial statements and prospects.

The investigation focuses on whether Nektar issued false and misleading statements regarding its business practices and prospects.  Specifically, Nektar failed to disclose that it lacked consistent and comprehensive quality controls for commercial-scale manufacturing for bempeg because (i) it lacked a comprehensive control strategy to limit variances in raw materials, intermediates and the final product in its manufacturing, and (ii) its CMC organization in terms of leadership and alignment of skills and activities was ineffective and required new leadership and structure.  Nektar’s lack of consistent and comprehensive quality controls resulted in flawed and defective clinical results for Nektar’s experimental cancer drug NKTR-214.